FR12C0034I2 - Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii - Google Patents

Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii

Info

Publication number
FR12C0034I2
FR12C0034I2 FR12C0034C FR12C0034C FR12C0034I2 FR 12C0034 I2 FR12C0034 I2 FR 12C0034I2 FR 12C0034 C FR12C0034 C FR 12C0034C FR 12C0034 C FR12C0034 C FR 12C0034C FR 12C0034 I2 FR12C0034 I2 FR 12C0034I2
Authority
FR
France
Prior art keywords
receptor antagonists
benzimidazole derivatives
benzimidazole
derivatives
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR12C0034C
Other languages
English (en)
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Lim
Original Assignee
Takeda Pharmaceutical Co Lim
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34858222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR12C0034(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical Co Lim filed Critical Takeda Pharmaceutical Co Lim
Publication of FR12C0034I1 publication Critical patent/FR12C0034I1/fr
Application granted granted Critical
Publication of FR12C0034I2 publication Critical patent/FR12C0034I2/fr
Active legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
FR12C0034C 2004-02-25 2012-05-11 Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii Active FR12C0034I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2004048928 2004-02-25
US11/031,057 US7157584B2 (en) 2004-02-25 2005-01-07 Benzimidazole derivative and use thereof
PCT/JP2005/003422 WO2005080384A2 (en) 2004-02-25 2005-02-23 Benzimidazole derivative and use as aii receptor antagonist

Publications (2)

Publication Number Publication Date
FR12C0034I1 FR12C0034I1 (fr) 2012-06-15
FR12C0034I2 true FR12C0034I2 (fr) 2013-01-11

Family

ID=34858222

Family Applications (1)

Application Number Title Priority Date Filing Date
FR12C0034C Active FR12C0034I2 (fr) 2004-02-25 2012-05-11 Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii

Country Status (34)

Country Link
US (3) US7157584B2 (forum.php)
EP (3) EP2119715B1 (forum.php)
JP (2) JP4256852B2 (forum.php)
KR (1) KR101080029B1 (forum.php)
CN (2) CN100503605C (forum.php)
AR (2) AR047972A1 (forum.php)
AT (2) ATE370136T1 (forum.php)
AU (1) AU2005214271B8 (forum.php)
BE (1) BE2012C025I2 (forum.php)
BR (2) BRPI0507984B8 (forum.php)
CA (1) CA2557538C (forum.php)
CY (5) CY1107008T1 (forum.php)
DE (3) DE602005002030T2 (forum.php)
DK (3) DK1718641T3 (forum.php)
ES (3) ES2293552T3 (forum.php)
FR (1) FR12C0034I2 (forum.php)
HR (3) HRP20070510T3 (forum.php)
HU (1) HUS1200008I1 (forum.php)
IL (1) IL177533A (forum.php)
LU (1) LU91962I2 (forum.php)
MA (1) MA28478B1 (forum.php)
ME (2) ME01089B (forum.php)
MY (1) MY142807A (forum.php)
NL (1) NL300802I2 (forum.php)
NO (2) NO332344B1 (forum.php)
NZ (1) NZ549755A (forum.php)
PL (3) PL2119715T3 (forum.php)
PT (3) PT1857457E (forum.php)
RS (3) RS50537B (forum.php)
RU (2) RU2369608C2 (forum.php)
SI (3) SI1857457T1 (forum.php)
TW (1) TWI336702B (forum.php)
WO (1) WO2005080384A2 (forum.php)
ZA (1) ZA200607241B (forum.php)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
CN102049048B (zh) 2004-12-24 2013-12-25 西芬克斯医药有限公司 治疗或预防的方法
JP4465469B2 (ja) * 2005-02-21 2010-05-19 国立大学法人佐賀大学 循環器病マーカーとしてのインターロイキン１３
US20090054502A1 (en) * 2005-03-30 2009-02-26 Takeda Pharmaceutical Company Limited Benzimidazole Derivative and Use as Angiotensin II Antagonist
WO2007097452A1 (ja) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬用ブリスターパッケージ
WO2007097451A1 (ja) * 2006-02-27 2007-08-30 Takeda Pharmaceutical Company Limited 医薬パッケージ
CA2646379C (en) 2006-03-20 2014-12-23 The University Of Queensland Method of treatment or prophylaxis inflammatory pain
ES2381507T3 (es) * 2006-09-25 2012-05-28 Takeda Pharmaceutical Company Limited Envase medicinal
WO2008123536A1 (en) * 2007-03-28 2008-10-16 Takeda Pharmaceutical Company Limited Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent
JP2009062296A (ja) * 2007-09-05 2009-03-26 Fujifilm Corp カルボン酸エステル化合物の製造方法
US20110038898A1 (en) * 2008-03-13 2011-02-17 Shuichi Yada Dissolution properties of drug products containing olmesartan medoxomil
MX2011001150A (es) * 2008-07-31 2011-03-29 Takeda Pharmaceutical Composicion farmaceutica solida.
TW201014850A (en) * 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
CA2741125A1 (en) * 2008-10-22 2010-04-29 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US9387249B2 (en) 2008-12-23 2016-07-12 Takeda Pharmaceutical Company Limited Methods of treating hypertension with at least one angiotensin II receptor blocker and chlorthalidone
US20110009347A1 (en) * 2009-07-08 2011-01-13 Yin Liang Combination therapy for the treatment of diabetes
KR101931209B1 (ko) 2010-05-11 2018-12-20 얀센 파마슈티카 엔.브이. Sglt의 억제제로서 1-(베타-d-글루코피라노실)-2-티에닐-메틸벤젠 유도체를 포함하는 약학 제형
WO2012090043A1 (en) 2010-12-29 2012-07-05 Jubilant Life Sciences Limited Novel solid state forms of azilsartan medoxomil and preparation thereof
US9233954B2 (en) 2011-01-20 2016-01-12 Jiangsu Hansoh Pharmaceutical Co., Ltd. Organic amine salts of Azilsartan, preparation method and use thereof
US9233955B2 (en) 2011-02-08 2016-01-12 Jubilant Life Sciences, Ltd. Process for the preparation of azilsartan medoxomil
CN102138899B (zh) * 2011-03-18 2013-08-21 海南本创医药科技有限公司 阿齐沙坦酯脂质体固体制剂
RS55056B1 (sr) 2011-04-13 2016-12-30 Janssen Pharmaceutica Nv Proces za pripremu jedinjenja koja su korisna kao inhibitori sglt2
CN102827153B (zh) * 2011-06-14 2016-10-05 江苏豪森药业集团有限公司 阿齐沙坦的晶型及其制备方法
CN102351853B (zh) * 2011-08-29 2014-03-12 石药集团欧意药业有限公司 一种阿齐沙坦酯化合物、制备方法及其药物组合物
WO2013042067A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of potassium salt of azilsartan medoxomil
WO2013042066A1 (en) 2011-09-20 2013-03-28 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil
BR112014014527A2 (pt) 2011-12-15 2017-06-13 Takeda Pharmaceuticals Usa Inc combinações de azilsartan e clorotalidona para tratar hipertensão em pacientes negros
WO2013088384A2 (en) 2011-12-15 2013-06-20 Jubilant Life Sciences Limited Solid state forms of azilsartan and azilsartan medoxomil monopotassium and preparation thereof
CN104039779B (zh) * 2012-01-14 2016-08-24 广东东阳光药业有限公司 阿齐沙坦酯钾的晶型及其制备方法及其用途
US20150011774A1 (en) * 2012-02-02 2015-01-08 Ranbaxy Laboratories Limited Process for the preparation of azilsartan medoxomil or pharmaceutically acceptable salts thereof
WO2013124748A1 (en) * 2012-02-20 2013-08-29 Alembic Pharmaceuticals Limited Novel polymorphs of azilsartan medoxomil potassium
CZ2012274A3 (cs) * 2012-04-19 2013-10-30 Zentiva, K.S. Zpusob prípravy vysoce cisté draselné soli azilsartanu medoxomilu
WO2013186792A2 (en) * 2012-06-11 2013-12-19 Msn Laboratories Limited Process for the preparation of (5-methyl-2-oxo-l,3-dioxoi-4-vl)methvl 2- ethoxv-l-{[2'-(5-oxo-4,5-dihvdro-l,2,4-oxadiazol-3-vl)biphenyi-4-vl]methyl}- lh-benzimidazole-7-carboxyiate and its salts
WO2014009969A2 (en) * 2012-07-09 2014-01-16 Hetero Research Foundation Novel polymorphs of azilsartan
WO2014020381A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Novel crystalline form of azilsartan medoxomil potassium
EP2925753A4 (en) 2012-08-27 2017-02-15 Hetero Research Foundation Novel polymorphs of azilsartan medoxomil
WO2014049512A2 (en) 2012-09-26 2014-04-03 Lupin Limited Novel process for preparation of azilsartan medoxomil
CZ305318B6 (cs) * 2012-09-26 2015-07-29 Zentiva, K.S. Způsob přípravy vysoce čisté draselné soli azilsartanu medoxomilu
CN105237527B (zh) * 2012-09-28 2018-03-06 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
AU2013329251A1 (en) * 2012-10-09 2015-04-30 Avery Dennison Corporation Adhesives and related methods
CN103910720A (zh) * 2013-01-07 2014-07-09 广东东阳光药业有限公司 阿齐沙坦酯的新晶型及其制备方法
CN105153141B (zh) * 2013-02-04 2018-09-25 武汉朗来科技发展有限公司 苯并咪唑衍生物及其制备方法和医药用途
JP6281735B2 (ja) * 2013-03-19 2018-02-21 トーアエイヨー株式会社 急性心不全治療薬の評価方法、及び、急性心不全モデルの作製方法
RU2535004C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
RU2535005C1 (ru) * 2013-06-11 2014-12-10 Николай Андреевич Козлов Способ лечения грыж межпозвонковых дисков у собак
CN104812752B (zh) * 2013-10-12 2016-09-28 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN105949183B (zh) * 2013-10-12 2019-02-22 杭州领业医药科技有限公司 阿齐沙坦酯的晶型及其制备方法
CN104774197B (zh) * 2014-01-09 2017-11-17 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN104774196B (zh) * 2014-01-09 2017-11-10 武汉朗来科技发展有限公司 一种苯并咪唑衍生物的制备方法
CN105079815A (zh) * 2014-04-30 2015-11-25 广东东阳光药业有限公司 一种阿齐沙坦酯钾组合物及其制备方法
CN104016974A (zh) * 2014-06-24 2014-09-03 浙江天宇药业股份有限公司 阿齐沙坦酯中间体及其合成方法、阿齐沙坦酯的合成方法
CZ2014702A3 (cs) 2014-10-15 2016-04-27 Zentiva, K.S. Způsob přípravy vysoce čistého azilsartanu
CN105622595A (zh) * 2014-11-21 2016-06-01 重庆朗天制药有限公司 一种阿奇沙坦酯钾盐及其中间体新的制备方法
CN105753854A (zh) * 2014-12-16 2016-07-13 重庆朗天制药有限公司 一种阿齐沙坦酯钾盐的新制备方法
US9708306B2 (en) 2015-03-18 2017-07-18 Wuhan Ll Science And Technology Development Co., Ltd Benzimidazole derivatives and preparation process and pharmaceutical uses thereof
CN106032378B (zh) * 2015-03-20 2019-10-25 武汉启瑞药业有限公司 新型arb化合物及其用途
CN104803998B (zh) * 2015-03-26 2017-08-25 晋江市托美汀生物科技有限公司 一种降低杂质含量的方法
JP2018521077A (ja) * 2015-07-29 2018-08-02 タケダ ゲー・エム・ベー・ハーＴａｋｅｄａ ＧｍｂＨ 糖尿病性腎症を治療するためのｐｄｅ４阻害剤
US20170071970A1 (en) 2015-09-15 2017-03-16 Janssen Pharmaceutica Nv Co-therapy comprising canagliflozin and phentermine for the treatment of obesity and obesity related disorders
JP6856365B2 (ja) * 2016-11-30 2021-04-07 株式会社トクヤマ アジルサルタンの製造方法
CN109071519A (zh) * 2016-01-28 2018-12-21 株式会社德山 阿齐沙坦及其制造方法
CN105628824B (zh) * 2016-03-06 2017-10-17 江苏正大清江制药有限公司 一种高效液相色谱法测定阿齐沙坦原料中有关物质的方法
CN112110909A (zh) * 2016-05-20 2020-12-22 武汉朗来科技发展有限公司 化合物及其制备方法、组合物和应用
CN105770876B (zh) * 2016-05-30 2019-09-10 广东天普生化医药股份有限公司 乌司他丁在制备治疗慢性前列腺炎药物中的用途
RU2623082C1 (ru) * 2016-07-11 2017-06-21 Государственное бюджетное образовательное учреждение высшего профессионального образования "Курский государственный медицинский университет" Министерства здравоохранения Российской Федерации Способ коррекции артериальной ригидности у больных ревматоидным артритом
EP3461822B1 (en) * 2016-07-11 2022-11-02 Wuhan LL Science And Technology Development Co., Ltd. Crystalline form of chemical compound, and preparation method, composition, and application thereof
RU2634272C1 (ru) * 2016-08-10 2017-10-24 Закрытое акционерное общество "Санкт-Петербургский институт фармации" Композиция с дезамино-аргинин-вазотоцином для парентерального введения и способ её получения
CN106074416A (zh) * 2016-08-30 2016-11-09 佛山市弘泰药物研发有限公司 一种阿齐沙坦酯钾盐分散片的制备方法
FI3524250T3 (fi) * 2016-10-08 2025-08-29 Wuhan Ll Science & Technology Development Co Ltd Neutraalia endopeptidaasin (nep) estäjää ja atsilsartaaniesterijohdannaista sisältävä farmaseuttinen koostumus ja sen käyttö sydän- ja verisuonitautien hoitoon
WO2019130277A1 (en) 2017-12-30 2019-07-04 Lupin Limited Pharmaceutical formulations of azilsartan medoxomil
CN110237071B (zh) * 2018-03-09 2022-03-22 武汉朗来科技发展有限公司 药物制剂及其应用
CN110237072B (zh) * 2018-03-09 2022-03-25 武汉朗来科技发展有限公司 药物组合物的制备方法
JP2021528735A (ja) 2018-06-14 2021-10-21 アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａ ＵＫ Ｌｉｍｉｔｅｄ アンジオテンシンｉｉ受容体遮断薬医薬組成物による高血圧症の治療方法
WO2019241519A1 (en) * 2018-06-14 2019-12-19 Astrazeneca Uk Limited Methods for lowering blood pressure with a dihydropyridine-type calcium channel blocker pharmaceutical composition
KR20200057662A (ko) 2018-11-16 2020-05-26 엠에프씨 주식회사 아질사르탄 유도체 화합물, 이의 중간체, 이의 제조방법 및 이를 포함하는 조성물
US11912688B2 (en) 2019-02-15 2024-02-27 Tohoku University 1, 3-dioxolane derivative
KR102220011B1 (ko) 2020-05-15 2021-02-25 대봉엘에스 주식회사 친환경 용매를 이용한 아질사탄의 제조방법 및 이에 관한 핵심 중간체 화합물
CN113912580B (zh) * 2021-11-03 2023-06-02 瑞孚信江苏药业股份有限公司 一种纯化4-(羟甲基)-5-甲基-[1,3]二氧杂环戊烯-2-酮的方法
TW202340183A (zh) 2021-12-28 2023-10-16 日商亞克醫藥股份有限公司 化合物、血管收縮素ii第一型受體拮抗劑及醫藥組合物
EP4606374A1 (en) * 2022-11-24 2025-08-27 Shanghai Aurora Biotechnology Co., Ltd. Pharmaceutical composition comprising azilsartan medoxomil potassium and calcium channel blocker, method for preparing same, and use thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62290071A (ja) 1986-06-09 1987-12-16 Matsushita Electric Ind Co Ltd 有機電解質二次電池
US5196444A (en) 1990-04-27 1993-03-23 Takeda Chemical Industries, Ltd. 1-(cyclohexyloxycarbonyloxy)ethyl 2-ethoxy-1-[[2'-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]benzimidazole-7-carboxylate and compositions and methods of pharmaceutical use thereof
US5616599A (en) 1991-02-21 1997-04-01 Sankyo Company, Limited Angiotensin II antagosist 1-biphenylmethylimidazole compounds and their therapeutic use
IS1756B (is) 1991-02-21 2000-12-28 Sankyo Company Limited Hliðstæðuaðferð til framleiðslu 1-Biphenylmethylimidazole afleiða
IL102183A (en) 1991-06-27 1999-11-30 Takeda Chemical Industries Ltd Biphenyl substituted heterocyclic compounds their production and pharmaceutical compositions comprising them
RU2117668C1 (ru) * 1991-10-23 1998-08-20 Эйсаи Ко., Лтд. Производное оксазолидона или его фармакологически приемлемые соли, фармацевтическая композиция, способ лечения
US5310929A (en) 1992-08-06 1994-05-10 E. I. Du Pont De Nemours And Company Prodrugs of imidazole carboxylic acids as angiotensin II receptor antagonists
JP2787539B2 (ja) * 1993-02-26 1998-08-20 松森　　昭 ウイルス性疾患の予防または治療剤
FR2708612B1 (fr) * 1993-08-05 1996-03-01 Roussel Uclaf Nouveaux dérivés bicycliques de l'imidazole, leur procédé de préparation, les nouveaux intermédiaires obtenus, leur application à titre de médicaments et les compositions pharmaceutiques les renfermant.
TW403748B (en) * 1994-11-02 2000-09-01 Takeda Chemical Industries Ltd An oxazolidinedione derivative, its production and a pharmaceutical composition for lowering blood sugar and lipid in blood comprising the same
US5610314A (en) 1995-04-03 1997-03-11 Bristol-Myers Squibb Company Process for preparing dioxolenone derivatives used for making prodrug esters and intermediates
DE19707628A1 (de) * 1997-02-26 1998-08-27 Merck Patent Gmbh Oxazolidinone
CN1441794A (zh) 2000-07-13 2003-09-10 武田药品工业株式会社 富脂质斑退化剂
CA2468827A1 (en) 2001-12-03 2003-06-12 Takeda Chemical Industries, Ltd. Insulin resistance improving agents
AU2003202488A1 (en) 2002-01-11 2003-07-30 Takeda Pharmaceutical Company Limited Coumarin derivatives, process for their production and use thereof
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
US6972258B2 (en) * 2003-08-04 2005-12-06 Taiwan Semiconductor Manufacturing Co., Ltd. Method for selectively controlling damascene CD bias
US7157584B2 (en) * 2004-02-25 2007-01-02 Takeda Pharmaceutical Company Limited Benzimidazole derivative and use thereof
JP4364171B2 (ja) 2005-07-15 2009-11-11 本田技研工業株式会社 自動車用ドアチェッカ

Also Published As

Publication number Publication date
TWI336702B (en) 2011-02-01
CY1109610T1 (el) 2014-08-13
ME01643B (me) 2010-05-07
ME01089B (me) 2013-03-20
BRPI0507984A (pt) 2007-07-24
CN100503605C (zh) 2009-06-24
CY2012016I1 (el) 2016-12-14
EP1857457B1 (en) 2009-08-19
AR047972A1 (es) 2006-03-15
KR101080029B1 (ko) 2011-11-04
AU2005214271A2 (en) 2005-09-01
HK1098472A1 (en) 2007-07-20
DE602005002030D1 (de) 2007-09-27
PL1857457T3 (pl) 2009-12-31
SI1857457T1 (sl) 2010-01-29
TW200530227A (en) 2005-09-16
CN1946717A (zh) 2007-04-11
RS50537B (sr) 2010-05-07
HK1115118A1 (en) 2008-11-21
AR094588A2 (es) 2015-08-12
PL1718641T3 (pl) 2008-01-31
CN101381366A (zh) 2009-03-11
AU2005214271B8 (en) 2011-03-03
JP4256852B2 (ja) 2009-04-22
WO2005080384A3 (en) 2006-09-28
CN101381366B (zh) 2011-06-15
MY142807A (en) 2011-01-14
CY2012016I2 (el) 2016-12-14
IL177533A (en) 2010-12-30
FR12C0034I1 (fr) 2012-06-15
ZA200607241B (en) 2008-04-30
DK2119715T3 (da) 2012-09-10
RS52376B (en) 2012-12-31
NO332344B1 (no) 2012-09-03
ES2331209T3 (es) 2009-12-23
KR20070020411A (ko) 2007-02-21
CY2012015I2 (el) 2016-12-14
ATE440095T1 (de) 2009-09-15
US20050187269A1 (en) 2005-08-25
RU2006133898A (ru) 2008-03-27
RU2501798C2 (ru) 2013-12-20
WO2005080384A9 (en) 2006-11-30
ES2388945T3 (es) 2012-10-22
EP2119715A1 (en) 2009-11-18
RU2009115498A (ru) 2010-10-27
DE602005002030T2 (de) 2008-05-08
AU2005214271A1 (en) 2005-09-01
ATE370136T1 (de) 2007-09-15
NO2012017I2 (no) 2012-11-09
IL177533A0 (en) 2006-12-10
NL300802I2 (forum.php) 2016-05-18
CA2557538A1 (en) 2005-09-01
DK1857457T3 (da) 2009-12-21
US20090270464A1 (en) 2009-10-29
EP2119715B1 (en) 2012-05-30
DE602005016162D1 (de) 2009-10-01
EP1857457A2 (en) 2007-11-21
HRP20090593T1 (hr) 2010-03-31
AU2005214271B2 (en) 2011-02-24
US20060281795A1 (en) 2006-12-14
RU2369608C2 (ru) 2009-10-10
DE122012000018I1 (de) 2012-06-06
EP1857457A3 (en) 2007-12-05
NO20064251L (no) 2006-11-22
US7572920B2 (en) 2009-08-11
BRPI0507984B8 (pt) 2023-03-21
LU91962I2 (fr) 2012-05-21
JP2009137974A (ja) 2009-06-25
PT1718641E (pt) 2007-11-15
RS51137B (sr) 2010-10-31
US7157584B2 (en) 2007-01-02
HUS1200008I1 (hu) 2017-06-28
EP1718641A2 (en) 2006-11-08
SI2119715T1 (sl) 2012-10-30
ES2293552T3 (es) 2008-03-16
CA2557538C (en) 2010-08-17
BR122012009489B8 (pt) 2023-03-21
BR122012009489B1 (pt) 2019-02-19
PT2119715E (pt) 2012-09-03
CY1113084T1 (el) 2016-04-13
PL2119715T3 (pl) 2012-10-31
NZ549755A (en) 2009-04-30
SI1718641T1 (sl) 2007-12-31
CY2012015I1 (el) 2016-12-14
BE2012C025I2 (forum.php) 2024-08-08
US7875637B2 (en) 2011-01-25
JP2005272451A (ja) 2005-10-06
DK1718641T3 (da) 2007-12-17
WO2005080384A2 (en) 2005-09-01
NO2012017I1 (no) 2012-11-26
EP1718641B1 (en) 2007-08-15
CY1107008T1 (el) 2012-09-26
HRP20070510T3 (hr) 2007-12-31
PT1857457E (pt) 2009-09-23
BRPI0507984B1 (pt) 2018-07-03
MA28478B1 (fr) 2007-03-01
HRP20120667T1 (en) 2012-09-30
HRP20120667T2 (hr) 2012-11-30

Similar Documents

Publication Publication Date Title
FR12C0034I2 (fr) Derives de benzimidazole et leur utilisation comme antagonistes du recepteur a ii
DK1720859T3 (da) Chemokinreceptorantagonister
EP2150115A4 (en) CYCLOPROPYLPYRROLIDINOREXIN Receptor Antagonists
EP1959959A4 (en) MORPHOLIN-CARBOXAMIDE PROKINETICIN RECEPTOR ANTAGONISTS
PL2513093T3 (pl) Nowi antagoniści receptora CCR2 i ich zastosowanie
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
BRPI0817245A2 (pt) Derivados e quinolina como antagonistas receptores de 5ht5a
EP1641781A4 (en) BENZODIAZEPINE-CGRP Receptor Antagonists
MA28359A1 (fr) Antagonistes du recepteur a l'hydroisoindoline tachykinine
DK2094709T3 (da) Thiazol-pyrazolopyrimidiner som CRF1-receptorantagonister
EP1954268A4 (en) SPIROLACTAM BICYCLIC CGRP RECEPTOR ANTAGONISTS
MA28815B1 (fr) Derives de indole-2-carboxamidine utilises comme antagonistes du recepteur nmda
IL237513A0 (en) Piperazindiones as oxytocin receptor antagonists
EP1951042A4 (en) TRICYCLIC SPIROLACTAM CGRP RECEPTOR ANTAGONISTS
HRP20160950T1 (hr) Polimorfi antagonista mglur5 receptora
EP1799672A4 (en) CGRP RECEPTOR ANTAGONIST
BRPI0820633A2 (pt) antagonistas de receptores de il-4 muteína modificada
ATE414078T1 (de) Indol-3-ylcarbonylpiperidinbenzimidazolderivate als v1a-rezeptorantagonisten
DE602005009355D1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
EP2150248A4 (en) GLUTAMATE RECEPTOR ANTAGONISTS AND METHOD OF USE
EP1734966A4 (en) Piperazinylpiperidine derivatives as chemokine receptor antagonists
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
EP2067480A4 (en) MUSCLIN RECEPTOR AND ITS USE
EP1534736A4 (en) ANTAGONISTS OF NOGO RECEPTOR
DE602005007719D1 (de) Antagonisten des opioidrezeptors